Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glyburide-induced hepatitis.

R C Goodman, P J Dean, A Radparvar

    Annals of Internal Medicine
    |June 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Sulfonylureas, like glyburide, rarely cause liver damage. This study reports two diabetes patients who developed hepatitis-like illness after taking glyburide, recovering after discontinuation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    An architectural understanding of natural sway frequencies in trees.

    Journal of the Royal Society, Interface·2019
    Same author

    FTO predicts weight regain in the Look AHEAD clinical trial.

    International journal of obesity (2005)·2013
    Same author

    Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.

    Diabetes, obesity & metabolism·2013
    Same author

    Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial.

    Endoscopy·2010
    Same author

    Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

    Diabetologia·2009
    Same author

    Is adiposopathy (sick fat) an endocrine disease?

    International journal of clinical practice·2008
    Same journal

    Correction to I.M. Matters News: Sleep medicine for seniors.

    Annals of internal medicine·2026
    Same journal

    Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

    Annals of internal medicine·2026
    Same journal

    Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

    Annals of internal medicine·2026
    Same journal

    Grappling with GLP-1 prescribing.

    Annals of internal medicine·2026
    See all related articles

    Area of Science:

    • Hepatology
    • Endocrinology
    • Pharmacology

    Background:

    • Drug-induced liver injury (DILI) is a significant clinical concern.
    • Sulfonylureas are commonly prescribed for type 2 diabetes mellitus.
    • Hepatotoxicity is an infrequent adverse event associated with sulfonylurea use.

    Observation:

    • Two patients with type 2 diabetes mellitus presented with acute hepatitis-like symptoms.
    • Symptoms emerged shortly after initiating glyburide therapy.
    • Viral hepatitis and other causes were ruled out through serologic testing and clinical evaluation.

    Findings:

    • Liver biopsy revealed histological patterns consistent with drug-induced hepatitis.
    • Both patients experienced rapid clinical improvement and full recovery after discontinuing glyburide.

    Related Experiment Videos

  • No recurrence of liver injury was observed during a one-year follow-up period.

    • Implications:

    • Glyburide, a second-generation sulfonylurea, can induce an acute hepatitis-like syndrome in susceptible individuals.
    • Clinicians should consider glyburide as a potential cause of acute liver injury in diabetic patients.
    • Prompt recognition and withdrawal of glyburide are crucial for managing this adverse drug reaction.